Exhibit 13

Meridian Bioscience, Inc. and Subsidiaries

SELECTED FINANCIAL DATA

Income Statement Information (Amounts in thousands, except per share data)

		FY 2010				FY 2009				FY 2008				FY 2007				FY 2006
Net sales		$	143,000			$	148,274			$	139,639			$	122,963			$	108,413
Gross profit			88,475				92,783				86,480				74,940				64,684
Operating income			41,138				48,779				44,350				35,030				26,894
Net earnings			26,647				32,759				30,202				26,721				18,333
Basic earnings per share		$	0.66			$	0.81			$	0.75			$	0.67			$	0.47
Diluted earnings per share		$	0.65			$	0.80			$	0.74			$	0.66			$	0.46
Cash dividends declared per share		$	0.74			$	0.65			$	0.53			$	0.40			$	0.28
Book value per share		$	3.38			$	3.40			$	3.19			$	2.83			$	2.40

Balance Sheet Information

		FY 2010				FY 2009				FY 2008				FY 2007				FY 2006
Current assets		$	94,020			$	117,147			$	99,458			$	93,745			$	80,742
Current liabilities			14,147				16,752				16,061				17,067				20,617
Total assets			154,785				155,997				146,431				132,698				120,528
Long-term debt obligations			—				—				—				—				1,803
Shareholders’ equity			137,361				137,905				128,489				112,948				94,350

FORWARD LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:

Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can also change expected results. One of Meridian’s main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. The Company cannot predict the possible impact of recently-enacted United States healthcare legislation and any similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.

Meridian Bioscience, Inc. and Subsidiaries

Corporate Data

Corporate Headquarters
3471 River Hills Drive
Cincinnati, Ohio 45244
(513) 271-3700

Legal Counsel
Keating Muething & Klekamp PLL
Cincinnati, Ohio

Independent Public Accountants
Grant Thornton LLP
Cincinnati, Ohio

Transfer Agent, Registrar and Dividend Reinvestment Administration
Shareholders requiring a change of name, address or ownership of stock, as well as information about shareholder records, lost or stolen certificates, dividend checks, dividend direct deposit, and dividend reinvestment should contact: Computershare Trust Company, P. O. Box 43078, Providence, RI 02940-3078; (888) 294-8217 or (781) 575-3120 (International holders only): e-mail web.queries@computershare.com; or submit your inquiries online through www.computershare.com/contactus.

Annual Meeting
The annual meeting of the shareholders will be held on Thursday, January 20, 2011 at 2:00 p.m. Eastern Time at the Holiday Inn Eastgate, 4501 Eastgate Boulevard, Cincinnati, OH 45245.
Directions to the Holiday Inn Eastgate can be found on our website: www.meridianbioscience.com.

Common Stock Information
NASDAQ Global Select Market Symbol: “VIVO.” Approximate number of beneficial holders: 19,700. Approximate number of record holders: 1,000.

The following table sets forth by calendar quarter the high and low sales prices of the Common Stock on the NASDAQ Global Select Market.

Years Ended September 30,		2010								2009
Quarter ended:		High				Low				High				Low
December 31			24.970				19.960				30.250				19.430
March 31			23.930				19.440				26.410				16.500
June 30			20.510				16.030				23.000				14.790
September 30			21.980				16.590				26.200				20.750

Directors and Officers

Directors

William J. Motto
Executive Chairman of the Board

John A. Kraeutler
Chief Executive Officer

James A. Buzard, Ph.D.
Retired Executive Vice President, Merrell Dow Pharmaceuticals, Inc.

Gary P. Kreider
Senior Partner, Keating Muething & Klekamp PLL

Robert J. Ready
Chairman of the Board and President, LSI Industries Inc.

David C. Phillips
Co-founder, Cincinnati Works, Inc.

James M. Anderson
Retired President and Chief Executive Officer, Cincinnati Children’s Hospital Medical Center

Officers and Executives

William J. Motto
Executive Chairman of the Board

John A. Kraeutler
Chief Executive Officer

Richard L. Eberly
Executive Vice President, President Meridian Life Science

Lawrence J. Baldini
Executive Vice President, Operations and Information Systems

Melissa A. Lueke
Executive Vice President, Chief Financial Officer and Secretary

Antonio A. Interno
Senior Vice President, President and Managing Director, Meridian Bioscience Europe

Susan D. Rolih
Senior Vice President, Regulatory Affairs and Quality Assurance

James A. Barter
Vice President, Sales and Marketing

Vecheslav A. Elagin
Vice President, Research and Development

Marviette Dale
Vice President, Human Resources

PERFORMANCE GRAPH

The following graph shows the yearly percentage change in Meridian’s cumulative total shareholder return on its Common Stock as measured by dividing the sum of (A) the cumulative amount of dividends, assuming dividend reinvestment during the periods presented and (B) the difference between Meridian’s share price at the end and the beginning of the periods presented; by the share price at the beginning of the periods presented with the Wilshire 5000 Equity Index and a Peer Group Index. The Peer Group consists of Alere Inc., Biomerica, Inc., IDEXX Laboratories, Inc., Life Technologies Corporation, Neogen Corporation, Orasure Technologies Inc., Quidel Corporation, Strategic Diagnostics Inc. and Trinity Biotech Plc.